OraSure Q3 Revenue Up 14% to $30.9M; Signs $13M Syntron/True Merger
OSUR sits 70% above its 52-week low of $2.08.
Summary
OraSure grew Q3 revenue 14% to $30.9 million with a 45.2% gross margin but still lost $13.1 million, and disclosed a same-day definitive agreement to acquire Syntron Bioresearch and True Diagnostics for $13.0 million upfront plus revenue-based earnouts.
Key Events · Earnings and Guidance · OSUR
-
Q3 Revenue Up 14% to $30.9M
Total net revenues rose to $30.9 million from $27.1 million a year earlier, with Diagnostics up 16% to $16.8 million and Sample Management Solutions up 21% to $12.5 million.
-
Loss Persists at $13.1M
GAAP net loss was $13.1 million, or $0.19 per diluted share, versus $13.7 million a year ago; gross margin improved to 45.2% from 43.5%.
-
$13M Syntron/True Merger Signed
On November 9, 2026 the company signed a definitive agreement for Syntron Bioresearch and True Diagnostics to become wholly-owned subsidiaries, with an aggregate upfront purchase price of $13.0 million in cash plus contingent consideration based on revenue targets through December 31, 2031; closing is expected in Q4 2026.
-
CT/NG Filing Withdrawn, $22.5M Non-Cash Gain
The July 2026 withdrawal of the CT/NG 510(k) eliminated the milestone contingent consideration and cut the royalty liability, producing a $22.5 million non-cash reduction in the nine-month period — an accounting benefit, not cash.
Analysis · OSUR · Industrial Applications And Services
Revenue growth and margin expansion are real, but the bigger news buried in this 10-Q is the November 9 definitive agreement to buy Syntron Bioresearch and True Diagnostics for $13.0 million upfront in cash, plus earnouts tied to revenue through 2031 — a bolt-on that will be funded from a cash pile that already fell to $148.2 million from $199.3 million this year. The quarter itself: revenue of $30.9 million, up 14%, gross margin 45.2% versus 43.5%, and a net loss of $13.1 million, or $0.19 per share, roughly flat with a year ago. The nine-month loss of $29.2 million looks much better than last year's $49.4 million only because of a $22.5 million non-cash reduction in contingent consideration after the company withdrew its CT/NG 510(k) in July 2026 — that is an accounting gain, not cash, and it also means the CT/NG product is further away than the deal terms assumed. Cash burn of $34.7 million over nine months against $148.2 million on hand leaves roughly three-plus years of runway at the current pace, before the new acquisition. The NowDiagnostics trade-secret case was resolved October 27, 2026 with a permanent injunction in OraSure's favor and all claims dismissed with prejudice, removing a legal overhang.
How filings like this one have moved
In the 30 days to Nov 9, 2026, 47.1% of the 1533 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.29%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, OSUR was trading at $3.53 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $243.5M. The 52-week trading range was $2.08 to $4.58. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.